CCP
SNNA

Clough Capital Partners’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Clough Capital Partners’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-136,228
Closed -$316K – 171
2018
Q4 		$316K Sell
136,228
-107,067
-44% -$944K 0.04% 128
2018
Q3 		$3.61M Sell
243,295
-49,400
-17% -$785K 0.34% 66
2018
Q2 		$4.45M Sell
292,695
-354,662
-55% -$6.02M 0.4% 67
2018
Q1 		$12.2M Sell
647,357
-137,952
-18% -$2.41M 1.16% 27
2017
Q4 		$14.2M Buy
785,309
+34,100
+5% +$721K 1.18% 28
2017
Q3 		$16.4M Buy
+751,209
New +$16.5M 1.1% 31

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Clough Capital Partners's SNNA Position: Q1 2019 in Review

Clough Capital Partners sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q1 2019, closing a stake of 136,228 shares — an estimated $316K sold.

Clough Capital Partners first reported a position in SNNA in Q3 2017 and held it in 6 quarters. The position peaked at $16.4M in Q3 2017. 57 funds tracked by Wall St. Rank hold SNNA as of Q1 2019.

  • Clough Capital Partners reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Clough Capital Partners sold 136,228 Sienna Biopharmaceuticals, Inc. shares in Q1 2019, an estimated $316K.
  • Clough Capital Partners first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 6 quarters.
  • Clough Capital Partners's Sienna Biopharmaceuticals, Inc. position peaked at $16.4M in Q3 2017.
  • 57 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q1 2019.

Based on Clough Capital Partners's 13F filing for Q1 2019, filed 15 May 2019.